Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia

Parinda A. Mehta, Mei Jie Zhang, Mary Eapen, Wensheng He, Adriana Seber, Brenda Gibson, Bruce M. Camitta, Carrie L. Kitko, Christopher C. Dvorak, Eneida R. Nemecek, Haydar A. Frangoul, Hisham Abdel-Azim, Kimberly A. Kasow, Leslie Lehmann, Marta Gonzalez Vicent, Miguel A. Diaz Pérez, Mouhab Ayas, Muna Qayed, Paul A. Carpenter, Sonata JodeleTroy C. Lund, Wing H. Leung, Stella M. Davies

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Children with hypodiploid acute lymphoblastic leukemia (ALL) have inferior outcomes despite intensive risk-adapted chemotherapy regimens. We describe 78 children with hypodiploid ALL who underwent hematopoietic stem cell transplantation between 1990 and 2010. Thirty-nine (50%) patients had ≤ 43 chromosomes, 12 (15%) had 44 chromosomes, and 27 (35%) had 45 chromosomes. Forty-three (55%) patients underwent transplantation in first remission (CR1) and 35 (45%) underwent transplantation in ≥ second remission (CR2). Twenty-nine patients (37%) received a graft from a related donor and 49 (63%) from an unrelated donor. All patients received a myeloablative conditioning regimen. The 5-year probabilities of leukemia-free survival, overall survival, relapse, and treatment-related mortality for the entire cohort were 51%, 56%, 27%, and 22%, respectively. Multivariate analysis confirmed that mortality risks were higher for patients who underwent transplantation in CR2 (hazard ratio, 2.16; P= .05), with number of chromosomes ≤ 43 (hazard ratio, 2.15; P= .05), and for those who underwent transplantation in the first decade of the study period (hazard ratio, 2.60; P= .01). Similarly, treatment failure risks were higher with number of chromosomes ≤ 43 (hazard ratio, 2.28; P= .04) and the earlier transplantation period (hazard ratio, 2.51; P= .01). Although survival is better with advances in donor selection and supportive care, disease-related risk factors significantly influence transplantation outcomes.

Original languageEnglish (US)
Pages (from-to)1273-1277
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume21
Issue number7
DOIs
StatePublished - Jul 1 2015

Bibliographical note

Funding Information:
The CIBMTR is supported by Public Health Service grant/cooperative agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI ; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); 2 grants, N00014-13-1-0039 and N00014-14-1-0028 , from the Office of Naval Research ; and grants from * Actinium Pharmaceuticals ; Allos Therapeutics, Inc. ; * Amgen ; an anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; * Blue Cross and Blue Shield Association ; * Celgene Corporation ; Chimerix, Inc. ; Fred Hutchinson Cancer Research Center ; Fresenius-Biotech North America, Inc. ; * Gamida Cell Teva Joint Venture Ltd. ; Genentech, Inc. ; * Gentium SpA ; Genzyme Corporation ; GlaxoSmithKline ; Health Research, Inc. Roswell Park Cancer Institute ; HistoGenetics ; Incyte Corporation ; Jeff Gordon Children's Foundation ; Kiadis Pharma ; Medac GmbH ; The Medical College of Wisconsin ; Merck & Co., Inc. ; Millennium: The Takeda Oncology Co. ; * Milliman USA, Inc. ; * Miltenyi Biotec ; National Marrow Donor Program; Onyx Pharmaceuticals ; Optum Healthcare Solutions, Inc. ; Osiris Therapeutics ; Otsuka America Pharmaceutical, Inc. ; Perkin Elmer, Inc. ; * Remedy Informatics ; * Sanofi US ; Seattle Genetics ; Sigma-Tau Pharmaceuticals ; Soligenix, Inc. ; St. Baldrick's Foundation ; StemCyte , A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc. ; Swedish Orphan Biovitrum ; * Tarix Pharmaceuticals ; * Terumo BCT ; * Teva Neuroscience, Inc. ; * Therakos ; University of Minnesota ; University of Utah ; and * WellPoint . The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration or any other agency of the US Government.

Publisher Copyright:
© 2015 American Society for Blood and Marrow Transplantation.

Keywords

  • Hematopoietic stem cell transplantation
  • Hypodiploid acute lymphoblastic leukemia

Fingerprint

Dive into the research topics of 'Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia'. Together they form a unique fingerprint.

Cite this